Rosenblatt Maintains Buy on Imax, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Rosenblatt analyst Steve Frankel maintains a Buy rating on Imax (NYSE:IMAX) but lowers the price target from $30 to $25.

February 13, 2024 | 6:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Rosenblatt maintains a Buy rating on Imax but lowers the price target from $30 to $25.
The reduction in price target by Rosenblatt could have a mixed impact on Imax's stock price. While maintaining a Buy rating indicates a positive outlook on the company, the lowered price target might cause some investors to adjust their expectations downwards, potentially leading to short-term price volatility.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100